Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Free Cash Flow (2017 - 2025)

Cue Biopharma (CUE) has disclosed Free Cash Flow for 9 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 88.08% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.9 million through Dec 2025, up 39.93% year-over-year, with the annual reading at -$21.9 million for FY2025, 39.93% up from the prior year.
  • Free Cash Flow hit -$1.1 million in Q4 2025 for Cue Biopharma, up from -$9.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q4 2025 to a low of -$12.9 million in Q2 2022.
  • Historically, Free Cash Flow has averaged -$9.0 million across 5 years, with a median of -$9.9 million in 2024.
  • Biggest YoY gain for Free Cash Flow was 91.79% in 2021; the steepest drop was 107.5% in 2021.
  • Year by year, Free Cash Flow stood at -$10.6 million in 2021, then rose by 1.22% to -$10.5 million in 2022, then dropped by 4.21% to -$11.0 million in 2023, then rose by 17.59% to -$9.0 million in 2024, then skyrocketed by 88.08% to -$1.1 million in 2025.
  • Business Quant data shows Free Cash Flow for CUE at -$1.1 million in Q4 2025, -$9.0 million in Q3 2025, and -$3.4 million in Q2 2025.